الفهرس 
ABSTRACTOnly 14 pages are availabe for public view
 |  | from | 108 |  |  |
| | | from | 108 | | |
Abstract
Background: Nanotechnology is a new branch of science, which is going to be a major driving
force behind the impending technological revolution in the 21st century. Although DOX is one of
the preferred chemotherapeutic drugs for the treatment of OSCC, several studies pointed out that it
was limited due to multidrug resistance (MDR) like the over-expression of DNA damage repair
agents as poly (ADP-ribose) polymerase-1 (PARP-1). Accordingly, it seemed very interesting to
explore the effect of DOX loaded mesoporous silica nanoparticles (MSNs) with their outstanding
properties in comparison to the conventional DOX on HNO-97 cell line, in an attempt to introduce a
novel efficient therapeutic modality for OSCC.
Aim: The objective of this study is to examine the anticancer effect of doxorubicin loaded MSNs on
HNSCC cell lines versus that of doxorubicin only, and to measure the expression of PARP-1 in
response to them
Methodology: we explored the effect of DOX alone and DOX loaded silica NPs on tongue SCC
(HNO-97) cell line. We tested the loading capacity and encapsulation efficiency of DOX on MSNs
at the beginning of the experiment. Cell line morphology was also assessed using inverted phase
contrast microscope. Then we analyzed the cell viability by Methyl Thiazol Tetrazolium (MTT)
assay and degree of apoptosis through expression of caspase-3 by flow cytometry. Finally, we
compared the expression PARP-1 in DOX and DOX loaded MSNs by ELISA.
Results: It was found that DOX/MSNs showed encapsulation efficiency of 46%. Cell line
morphology showed loss of cell adherence, decrease in number and change in shape, which was
viii
more relevant in DOX/MSNs. In comparison, DOX/MSNs showed superior results to DOX in
reduction of cell viability percentage and elevation of caspase-3. In addition, the expression of
PARP-1 showed the least value in the DOX/MSNs followed by DOX then the control group.
Conclusions: In conclusion, using MSNs in DOX delivery to cancer cells contribute in therapeutic
effectiveness of the drug with and help to overcome MDR of HNO-97.